A Real World Study of Aducanumab Treatment in Patients with Early Alzheimer’s Disease in China

Abstract

Background: The aggregation of amyloid‐β (Aβ) is widely regarded as a key factor in the pathogenesis of Alzheimer’s disease (AD). The aducanumab was the first anti‐Aβ monoclonal body clinically used in China.

The paper